Effects of betulinic acid on AKT/mTOR pathway in renal cell carcinoma.


Journal

Turkish journal of urology
ISSN: 2149-3235
Titre abrégé: Turk J Urol
Pays: Turkey
ID NLM: 101643563

Informations de publication

Date de publication:
Jan 2022
Historique:
entrez: 4 2 2022
pubmed: 5 2 2022
medline: 5 2 2022
Statut: ppublish

Résumé

Renal cancer is the most lethal among urological cancer. Treatments of renal cell carcinoma (RCC) may be possible by immune checkpoint inhibitors and drug treatment targeting different molecules. We aimed to determine the apoptotic effect of betulinic acid and its effects on expressions of apoptosisassociated genes AKT-1 and mTOR in RCC cells. In this study, we investigated the apoptotic activity of betulinic acid in CAKI-2 cell line and its effect on AKT-1 and mTOR gene expression levels. In order to do so, following analyses were conducted: WST-1 to identify the toxic effect of betulinic acid, Caspase-3/BCA to detect caspase enzyme activity, Annexin-V and ELISA to determine for apoptotic effect, and finally, real-time PCR for expression levels of AKT-1 and mTOR. Our study showed that different concentrations of betulinic acid induced apoptosis in renal cancer; however, no effect was observed in healthy cells. In gene expression analysis, there was statistically significant decrease in AKT-1 expression level while increasing mTOR expression level. We suggested that betulinic acid with its apoptotic effect on RCC line and nontoxic effect on healthy cell line and the effects on AKT/mTOR pathway may be a potential anticancer drug promising for future studies.

Identifiants

pubmed: 35118990
doi: 10.5152/tud.2022.21276
pmc: PMC9612733
doi:

Types de publication

Journal Article

Langues

eng

Pagination

58-63

Références

Molecules. 2018 Sep 09;23(9):
pubmed: 30205592
Phytochemistry. 2019 Jun;162:241-249
pubmed: 30959403
Leuk Lymphoma. 2014 Sep;55(9):1980-92
pubmed: 24295132
Molecules. 2018 Aug 22;23(9):
pubmed: 30135395
Molecules. 2015 Jan 19;20(1):1610-25
pubmed: 25608043
Int J Mol Med. 2017 Dec;40(6):1669-1678
pubmed: 29039440
Anticancer Res. 2019 Jul;39(7):3835-3845
pubmed: 31262911
J Cell Mol Med. 2019 Jan;23(1):586-595
pubmed: 30417527
Molecules. 2017 Feb 10;22(2):
pubmed: 28208611
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593
Planta Med. 2019 Aug;85(11-12):802-814
pubmed: 30658371
Biomed Pharmacother. 2018 Jul;103:198-203
pubmed: 29653365
Lancet. 2016 Feb 27;387(10021):894-906
pubmed: 26318520
Anticancer Drugs. 2009 Nov;20(10):880-92
pubmed: 19745720
Semin Cancer Biol. 2013 Feb;23(1):46-55
pubmed: 22705279
J Biol Chem. 1998 Dec 18;273(51):33942-8
pubmed: 9852046
Life Sci. 2018 Sep 15;209:24-33
pubmed: 30076920
Cell Death Dis. 2014 Apr 10;5:e1169
pubmed: 24722294
Nat Rev Dis Primers. 2017 Mar 09;3:17009
pubmed: 28276433
Eur Urol. 2019 Jan;75(1):74-84
pubmed: 30243799
Bioorg Med Chem. 2019 Jun 15;27(12):2546-2552
pubmed: 30910472
Biotechnol Adv. 2020 Jan - Feb;38:107409
pubmed: 31220568
Semin Cancer Biol. 2018 Feb;48:91-103
pubmed: 28467889
Mol Biosyst. 2015 Jul;11(7):1946-54
pubmed: 25924008
Biomolecules. 2019 Jul 03;9(7):
pubmed: 31277238
Int J Cancer. 2010 Jul 15;127(2):282-92
pubmed: 19937797
Cancer Treat Rev. 2017 Nov;60:77-89
pubmed: 28898679
Eur J Med Chem. 2017 May 5;131:222-236
pubmed: 28329729
J Genet Genomics. 2015 Jul 20;42(7):343-53
pubmed: 26233890

Auteurs

Merve Nur Ataş (MN)

Department of Molecular Medicine, Aziz Sancar Institute of Experimental Medicine, Istanbul University, Istanbul, Turkey.

Barış Ertuğrul (B)

Department of Molecular Medicine, Aziz Sancar Institute of Experimental Medicine, Istanbul University, Istanbul, Turkey.

Elif Sinem İplik (ES)

Department of Biochemistry, Istanbul Health and Technology University Faculty of Medicine, Istanbul, Turkey.

Bedia Çakmakoğlu (B)

Department of Molecular Medicine, Aziz Sancar Institute of Experimental Medicine, Istanbul University, Istanbul, Turkey.

Arzu Ergen (A)

Department of Molecular Medicine, Aziz Sancar Institute of Experimental Medicine, Istanbul University, Istanbul, Turkey.

Classifications MeSH